RT Book, Section
A1 Gada, Hemal
A1 Kodali, Susheel
A2 Samady, Habib
A2 Fearon, William F.
A2 Yeung, Alan C.
A2 King III, Spencer B.
SR Print(0)
ID 1146603641
T1 Balloon-Expandable Transcatheter Aortic Valve Replacement
T2 Interventional Cardiology, 2e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9780071820363
LK accesscardiology.mhmedical.com/content.aspx?aid=1146603641
RD 2024/04/20
AB Transcatheter  aortic  valve  replacement  (TAVR)  has  been  shown  to  improve  mortality  and  quality  of  life  in  patients  with  severe  aortic  stenosis  who  are  designated  inoperable  or  high  risk  for  surgical  aortic  valve  replacement  (SAVR).1-5  The  first  implantation  of  a  transcatheter  heart  valve  (THV)  in  the  aortic  position  was  performed  by  Cribier  et  al6  to  treat  an  inoperable  patient  with  severe  symptomatic  aortic  stenosis.  From  the  development  of  the  porcine  model  to  the  first  clinical  implantation  in  the  aortic  position,  the  makeup  of  a  THV  was  a  foldable  biological  cardiac  valve  sewn  inside  an  expandable  stent  frame.  This  device  would  be  crimped  onto  a  balloon  in  order  to  deploy  the  THV  via  inflation.  With  this  concept,  the  technology  has  emerged  as  one  of  the  most  transformative  in  the  field  of  interventional  cardiology.  Given  the  initial  focus  on  development  of  a  balloon-expandable  THV  to  facilitate  TAVR,  the  largest  experiences  with  TAVR  are  with  balloon-expandable  THVs.  The  main  objectives  of  this  chapter  are  to  review  the  available  devices,  methods  of  implantation,  clinical  outcomes,  valve  hemodynamics,  and  durability  associated  with  these  systems.